Regensight is an Italian start-up company based in Rome. It has developed a breakthrough platform based upon theranostic technology for correcting major visual disorders at all ages and is clinically validating it. Theranostics is a breakthrough medical solution based on therapy guided by imaging diagnostics for providing tailored therapies. The Regensight platform improves vision by inducing the controlled photo-polymerization process of corneal tissue proteins through UV-A light mediated delivery and photo-activation of a bio-chromophore in the cornea.

Regensight for treatment of visual disorders
 

Patents:
■ “Process for dosing a chromophoric agent in a corneal tissue and apparatus for controlling the dose“.IT102016000007349, EP3407920, US20210196511 e CN108697814B

■ “Device, system and method for treating a corneal tissue”. IT102019000010341, EP3989895, US20220233842 e CN114025835

■ “Liquid formulation, in particular to treat a corneal tissue“. IT102019000011985, US20230131004 e CN114126650

TRL 9 for the treatment of Keratoconus.
TRL 4 for the treatment of Myopia e Presbyopia.

Download leaflet